We are evaluating the safety and efficacy of LB-102 for schizophrenia in multiple clinical trials.
Clinical Trials
Ongoing Phase 2 Clinical Trial of LB-102:
We are currently conducting a Phase 2 clinical trial to test LB-102 in patients with acute schizophrenia. This trial (NCT06179108) aims to evaluate the efficacy and safety of LB-102. Here’s what you need to know:
Trial Details
The trial involves patients who have shown clinical response to previous antipsychotic treatments (except clozapine) in the prior 12 months. It is a double-blind, randomized, placebo-controlled trial, meaning neither the patients nor the researchers know who is receiving LB-102 or a placebo.
Dosing
Patients will start with a seven-day period to clear previous medications from their system. They will then receive daily doses of LB-102 (50 mg, 75 mg, or 100 mg) or a placebo for four weeks. We are testing different doses to find the most effective and safest option.
Goals
The main goal is to see how well LB-102 works compared to the placebo by measuring changes in schizophrenia symptoms using the PANSS (Positive and Negative Syndrome Scale) score over four weeks.
